Retatrutide is a synthetic triple-receptor agonist peptide targeting the GLP-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR) simultaneously, studied extensively across metabolic biology, obesity research, energy expenditure, and cardiovascular science for its unmatched tri-agonist incretin action and superior metabolic influence compared to single and dual-receptor compounds making it the most advanced and broadly acting incretin research peptide currently available in modern metabolic science
Nicotinamide nucleotide transhydrogenase transfers the hydrogen between NAD(P)H and NAD(P) + , and is found in eukaryotic mitochondria and many bacteria
Diabetic eye disease (retinopathy)
1 Comparison of (a) recurrent suicidal ideations and (b) medication prescriptions for suicidal ideations treatments in patients with type 2 diabetes (T2DM) who had a prior history of suicidal ideations between propensity-score matched semaglutide and non-GLP1R agonist anti-diabetes medications groups for 6-month follow-up period
If you have questions about Semaglutide, or other weight loss treatments that may be right for you, please contact us for a consultation
GLP-1 receptor agonists represent the most commonly prescribed weight loss injections